Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer
Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Forty years ago clinical studies conducted by Ewan Cameron and Linus Pauling suggested that
intravenous (IV) and oral ascorbic acid (AA) may diminish symptoms and could improve survival
in terminal cancer patients. Previous phase I and II clinical trials have found that high
dose (1.5g/kg ) iv AA is well tolerated in cancer patients. This is a phase I/II, randomized
study of parenteral administration of Ascorbic Acid (AA) as a supplement to the conventional
neo-adjuvant chemotherapy in women with breast cancer.